Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$5,807 Mln
P/E Ratio
246.47
P/B Ratio
26.11
Industry P/E
--
Debt to Equity
1.14
ROE
0.12 %
ROCE
6.26 %
Div. Yield
0 %
Book Value
1.39
EPS
0.15
CFO
$-1,214.56 Mln
EBITDA
$-1,438.86 Mln
Net Profit
$-1,500.88 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
TG Therapeutics (TGTX)
| 26.21 | -11.63 | 27.23 | 175.69 | 72.35 | 25.44 | 8.65 |
|
BSE Sensex*
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
TG Therapeutics (TGTX)
| 75.42 | 44.38 | -37.74 | -63.48 | 368.65 | 170.73 | -49.81 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.48 | 9,808.03 | 20.22 | 23.13 | |
| 282.28 | 8,956.09 | 22.08 | 58.42 | |
| 25.74 | 9,559.25 | -- | -28.77 | |
| 101.74 | 10,030.35 | 30.81 | 14.16 |
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an... anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. The company was incorporated in 1993 and is based in Morrisville, North Carolina. Address: 3020 Carrington Mill Blvd., Morrisville, NC, United States, 27560 Read more
Chairman, CEO & President
Mr. Michael S. Weiss Esq.
Chairman, CEO & President
Mr. Michael S. Weiss Esq.
Headquarters
Morrisville, NC
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of TG Therapeutics Inc (TGTX) stood at $ 578 Mln as on 31-Dec-24
The share price of TG Therapeutics Inc (TGTX) is $37.99 (NASDAQ) as of 22-Apr-2025 16:00 EDT. TG Therapeutics Inc (TGTX) has given a return of 72.35% in the last 3 years.
TG Therapeutics Inc (TGTX) has a market capitalisation of $ 5,807 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/E ratio of TG Therapeutics Inc (TGTX) is 246.47 times as on 22-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the TG Therapeutics Inc (TGTX) and enter the required number of quantities and click on buy to purchase the shares of TG Therapeutics Inc (TGTX).
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. The company was incorporated in 1993 and is based in Morrisville, North Carolina. Address: 3020 Carrington Mill Blvd., Morrisville, NC, United States, 27560
The CEO & director of Mr. Michael S. Weiss Esq.. is TG Therapeutics Inc (TGTX), and CFO & Sr. VP is Mr. Michael S. Weiss Esq..
There is no promoter pledging in TG Therapeutics Inc (TGTX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| TG Therapeutics Inc. (TGTX) | Ratios |
|---|---|
|
Return on equity(%)
|
12.21
|
|
Operating margin(%)
|
15.08
|
|
Net Margin(%)
|
7.11
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of TG Therapeutics Inc (TGTX) was $0 Mln.
$1.02
(
